SCHEMBL6760774

SCHEMBL6760774

Nc1ccc(S(=O)(=O)Nc2ccc3nsnc3c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 1/20 0.64
▸ EEF2K O00418 1/20 0.64
▸ PLK4 O00444 1/20 0.64
▸ AURKA O14965 1/20 0.64
▸ DYRK3 O43781 1/20 0.64
▸ RPS6KA5 O75582 1/20 0.64
▸ PRKD3 O94806 1/20 0.64
▸ MAP4K4 O95819 1/20 0.64
▸ PIM1 P11309 1/20 0.64
▸ PHKG2 P15735 1/20 0.64
▸ CDK2 P24941 1/20 0.64
▸ AKT1 P31749 1/20 0.64
▸ AKT2 P31751 1/20 0.64
▸ MAPK8 P45983 1/20 0.64
▸ MAPKAPK2 P49137 1/20 0.64
▸ GSK3A P49840 1/20 0.64
▸ GSK3B P49841 1/20 0.64
▸ RPS6KA3 P51812 1/20 0.64
▸ PRKX P51817 1/20 0.64
▸ NEK2 P51955 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764847 0.85 PIK3CD (0.68) CDC7EEF2KPLK4AURKADYRK3
SCHEMBL8541050 0.85 PIK3CD (0.57) HTR6HSPD1PTPN2PTPN1PTPN5
SCHEMBL8313917 0.85 POLB (0.58) CDC7EEF2KPLK4AURKADYRK3
SCHEMBL8315471 0.82 ALDH1A1 (0.56) HSPD1PTPN2PTPN1PTPN5HSPE1
SCHEMBL8315991 0.82 PTPN1 (0.52) CDC7EEF2KPLK4AURKADYRK3
SCHEMBL6762244 0.82 TXNRD1 (0.59) HSPD1PTPN2PTPN1PTPN5HSPE1
SCHEMBL8317574 0.81 PIK3CD (0.54) HSPD1PTPN2PTPN1PTPN5HSPE1
SCHEMBL8313217 0.79 CDC7 (0.64) CDC7EEF2KPLK4AURKADYRK3
SCHEMBL540915 0.77 CA1 (0.85) AKT1HTR6CA1CA2HTT
SCHEMBL11793140 0.77 CA1 (0.85) AKT1HTR6CA1CA2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063731-A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists MERCK PATENT GMBH (DE) 2004-04-01 — — US claimed
EP-1357915-A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS MERCK PATENT GmbH (DE) 2003-11-05 — — EP claimed
WO-2002062343-A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2002-08-15 — — WO claimed
EP-0733626-B1 N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists MERCK PATENT GMBH (DE) 1999-01-13 — — EP claimed
EP-0733626-A1 N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists MERCK PATENT GmbH (DE) 1996-09-25 — — EP claimed
JP-8269027-A — — None — — JP disclosed
US-20040063731-A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists MERCK PATENT GMBH (DE) 2004-04-01 — — US disclosed
EP-1357915-A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS MERCK PATENT GmbH (DE) 2003-11-05 — — EP disclosed
WO-2002062343-A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2002-08-15 — — WO disclosed
EP-0733626-B1 N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists MERCK PATENT GMBH (DE) 1999-01-13 — — EP disclosed
US-5726194-A Endothelin receptor antagonists MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1998-03-10 — — US disclosed
JP-H08269027-A ENDOTHELIN RECEPTOR ANTAGONIST MERCK PATENT GMBH 1996-10-15 — — JP disclosed
EP-0733626-A1 N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists MERCK PATENT GmbH (DE) 1996-09-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063731-A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists EDNRA, EDNRB, PTGIR CDC7 2777/4885EEF2K 905/4885PLK4 2327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback